Aducanumab, or Aduhelm, is the first new Alzheimer’s treatment in 18 years and the first to attack the disease process. But some prominent experts say there’s not enough evidence it can address cognitive symptoms.
What to Expect from a Potential Trump Administration in 2025
As Donald Trump campaigns for a potential return to the presidency, speculation grows about what his administration might prioritize and how it would shape the
